Browsing Tag
glioblastoma
16 posts
Telix Pharmaceuticals (TLX) gains European review momentum for TLX101-Px brain cancer imaging candidate
Telix has a glioma imaging gap to fill. Europe’s TLX101-Px review could test whether radiopharma can move beyond prostate cancer.
From lab validation to clinical execution: Adaptin Bio advances a novel glioblastoma therapy toward trials
Find out how Adaptin Bio is moving a novel glioblastoma therapy from lab validation into early clinical execution and what this step means for brain cancer research.
Curasight enters clinic with uTREAT for glioblastoma, advancing dual radiopharma strategy
Curasight starts first-in-human trial of uTREAT in glioblastoma, launching its therapeutic radiopharmaceutical program. Read the full strategic analysis.
Glioblastoma trial for MT027 moves forward as T-MAXIMUM debuts allogeneic cell therapy in CNS
T-MAXIMUM wins FDA clearance for MT027 in glioblastoma. Read how its non-viral, off-the-shelf CAR-T may reshape solid tumor cell therapy development.
Black Diamond Therapeutics reports strong early Phase 2 response for silevertinib in first-line NSCLC patients
Discover how Black Diamond Therapeutics’ silevertinib achieved a 60% response in first-line lung cancer and why its upcoming glioblastoma trial could reshape targeted oncology.
Metastatic TNBC sees unexpected remission as Kazia Therapeutics’ Q4 update reveals pipeline momentum across cancer programs
Learn how Kazia Therapeutics’ rare iCR in metastatic TNBC is reshaping its breast cancer, immuno-oncology, and GBM pipeline strategy.
Why OSR Holdings (NASDAQ: OSRH) chose its scientific founder to lead Vaximm’s next immunotherapy chapter
OSR Holdings appoints scientific founder Dr. Andreas Niethammer as CEO of Vaximm AG to lead next-gen cancer immunotherapy strategy. Read more.
How Northwest Biotherapeutics’ acquisition of Advent BioServices may reshape its cell therapy strategy
Northwest Biotherapeutics acquires Advent BioServices to scale DCVax production and integrate UK manufacturing. Find out what this means for its immunotherapy pipeline.
Telix Pharmaceuticals (ASX: TLX) jumps 16% after CMS greenlight and Illuccix’s European rollout
Telix Pharmaceuticals raises FY25 revenue guidance after securing CMS reimbursement for Gozellix and accelerating Illuccix's launch in Europe. Learn what’s next.
EMA clears Curasight’s uTREAT trial—will targeted radiopharma redefine brain cancer therapy?
Curasight wins EMA approval for its first uTREAT clinical trial in glioblastoma. Find out how its theranostic strategy could change brain cancer treatment.